中国医学工程2025，Vol.33Issue(4)：63-67,5.DOI:10.19338/j.issn.1672-2019.2025.04.013
TACE辅助免疫靶向治疗对晚期不可切除肝内胆管细胞癌的临床研究
Clinical study of TACE assisted immunotargeted therapy for advanced unresectable intrahepatic cholangiocarcinoma
摘要
Abstract
[Objective]To observe the clinical efficacy of TACE assisted immunotargeted therapy for advanced unresectable intrahepatic cholangiocarcinoma.[Methods]This article focused on 106 cases of advanced unresectable intrahepatic cholangiocarcinoma treated in the First Affiliated Hospital of Zhengzhou University from January 2021 to February 2023.A prospective randomized controlled clinical trial was conducted,and the enrolled patients were divided into the conventional group(53 cases)and the TACE group(53 cases)based on computer random grouping method.The conventional group received conventional immunotherapy and targeted therapy,while the TACE group received TACE adjuvant immunotherapy and targeted therapy.Both groups were followed up for one year after treatment to compare their tumor marker levels,immune function,recent efficacy,and short-term survival.[Results]Under different treatment regimens,the CEA,CA242,and CA199 of the TACE group were 20.33±5.28 ng/mL,21.45±5.33 U/mL,and 42.19±10.44 U/mL,lower than the conventional group(23.39±5.34 ng/mL,24.49±5.28 U/mL,and 47.65±10.22 U/mL)(P<0.05).The CD3+,CD4+,and CD4+/CD8+levels in the TACE group were 70.24%±10.33%,71.25%±10.45%,and 1.75±0.45,higher than the conventional group(65.22%±10.41%,66.39%±10.27%,and 1.26±0.77)(P<0.05).The objective response rate(ORR)and disease control rate(DCR)of the TACE group were 84.91%(45/53)and 90.57%(48/53),higher than the conventional group[60.38%(32/53)and 67.92%(36/53)](P<0.05).As of the end of follow-up,the one-year survival rate,median progression free survival(PFS),and median overall survival(OS)of TACE group were 86.79%(46/53),10.23±2.15 months,and 11.35±2.44 months,higher than the conventional group[66.04%(35/53),9.27±1.52 months,and 10.34±2.15 months](P<0.05).The incidence of chemotherapy related side effects in the TACE group was 28.30%(15/53),slightly higher than the conventional group[24.53%(13/53)](P>0.05).[Conclusion]TACE assisted immunotargeted therapy for advanced unresectable intrahepatic cholangiocarcinoma can enhance the anti-tumor effect and improve the patient's immune function,which has a positive significance in improving short-term efficacy and prognosis.关键词
不可切除肝内胆管细胞癌/肝动脉化疗栓塞术/免疫治疗/靶向治疗/预后情况Key words
non-resectable intrahepatic cholangiocarcinoma/hepatoarterial chemoembolization/immunotherapy/targeted therapy/prognostic situation分类
医药卫生引用本文复制引用
彭茴茴,李媛,孟德敏..TACE辅助免疫靶向治疗对晚期不可切除肝内胆管细胞癌的临床研究[J].中国医学工程,2025,33(4):63-67,5.基金项目
河南省医学科技攻关项目(LHGJ202001341) （LHGJ202001341）
